KRYS · CUSIP 501147102
Krystal Biotech
Reported by 1 of 79 curated managers in Q2 2026, in the holdings snapshot last exported 2026-10-26.
- Managers holding
- 1
- Average portfolio weight
- 0.6%
- Combined reported value
- $4.5M
- Research group
- 79
1 of the 79 superinvestors Shameless Cloning tracks reported Krystal Biotech (KRYS) in their Q2 2026 13F filings, worth $4.5M combined, at an average 0.6% of their portfolios. The largest positions by portfolio weight belong to Torray Funds (0.6%).
Reporting managers
This is a historical 13F snapshot, not a live shareholder register. The count covers all matched managers; dashboard rankings use only those with at least 95% coverage. Reported value is measured at filing quarter-end, not at today's price.
| Manager / SEC filer | % of portfolio | Reported value |
|---|---|---|
| Torray FundsTorray Investment Partners LLC | 0.6% | $4.5M |